L3VLUP
ProSign in

AXSM · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AXSMVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • AXSM
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterAXSMVRTX
Q3 20201 holders, $2.1m31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 20211 holders, $2.5m31 holders, $15.4bn
Q2 2021none listed holders, n.a.30 holders, $12.7bn
Q3 20212 holders, $12m35 holders, $10.1bn
Q4 2021none listed holders, n.a.28 holders, $12.4bn
Q1 20222 holders, $12m23 holders, $16.1bn
Q2 20221 holders, $2.6m25 holders, $18.1bn
Q3 20222 holders, $37m22 holders, $18.4bn
Q4 20224 holders, $75m28 holders, $18.4bn
Q1 20234 holders, $146m26 holders, $21.4bn
Q2 20236 holders, $92m27 holders, $24.7bn
Q3 20234 holders, $78m33 holders, $24.3bn
Q4 20234 holders, $120m32 holders, $28.6bn
Q1 20243 holders, $59m31 holders, $29.8bn
Q2 20244 holders, $65m29 holders, $33.4bn
Q3 20246 holders, $86m27 holders, $33.5bn
Q4 20243 holders, $38m26 holders, $28.5bn
Q1 20259 holders, $222m21 holders, $35.4bn
Q2 20257 holders, $139m21 holders, $32.3bn
Q3 20255 holders, $284m22 holders, $25.9bn
Q4 202512 holders, $806m26 holders, $31.8bn
Q1 202612 holders, $708m25 holders, $31.8bn
Q2 202617 holders, $1.4bn26 holders, $34.6bn
AXSM

Axsome Therapeutics Inc

Holders
12
Reported value
$806m
Buyers
15
Sellers
12

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$31.8bn
Buyers
19
Sellers
20

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only AXSM (4)

D. E. Shaw & Co., Farallon Capital Management LLC, PDT Partners LLC, Quantbot Technologies LP

Only VRTX (18)

Acadian Asset Management LLC, AllianceBernstein LP, ARK Investment Management LLC, Arrowstreet Capital LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Squarepoint Ops LLC, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →